Key facts
- This page summarizes Daniel H. Schneiderman's Form 4 filing for Pasithea Therapeutics Corp. (KTTA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Dec 2025, 09:04.
Daniel H. Schneiderman - 28 Nov 2025 Form 4 Insider Report for Pasithea Therapeutics Corp. (KTTA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- KTTA
- Reported as of
- 28 Nov 2025
- Net transaction value
- +$20,000
- SEC form
- 4
- Accepted by SEC
- 01 Dec 2025, 09:04:30 UTC
- Prior SEC filing
- 27 Oct 2025
- Next SEC filing
- 05 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Schneiderman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel H. Schneiderman filed Form 4 for Pasithea Therapeutics Corp. (KTTA) on 01 Dec 2025.
Change
- Previous filing in this sequence was filed on 27 Oct 2025.
- Current net transaction value: +$20,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001565536
Primary reporting owner
Schneiderman Daniel H
- Relationship
- Chief Financial Officer
- Address
- 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
- Signature
- /s/ Daniel Schneiderman
- Signature date
- 01 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KTTA
transaction
Common Stock
Award
- Transaction value
- $20,000
- Shares
- +26,667
- Change %
- Price
- $0.7500
- Shares after
- 26,667
- Date
- 28 Nov 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.